Brussels, 4 June – Today’s announcement from the EU Council of Ministers on the revision of the General Pharmaceutical Legislation represents a missed opportunity to position Europe’s life sciences sector at the forefront of global competition.

In the face of a highly disruptive and unpredictable global environment, Europe needs clarity, stability, and a future-proof regulatory framework to support pharmaceutical innovation. While a significant number of EU member states have acknowledged the urgency of reinforcing Europe’s competitive edge, the text falls short of delivering the bold action Europe needs.

The choice to reduce intellectual property protections for pharmaceutical companies makes Europe less attractive, discouraging investment and jeopardising the development of innovative treatments in Europe without addressing the underlying barriers and delays to patient access.

As the legislative process enters its final phase, EFPIA urges EU decision-makers to consider the long-term consequences. If Europe is to remain competitive and continue to deliver cutting-edge healthcare solutions, it must provide a predictable and globally competitive environment for research, development and manufacturing.